May 7 (Reuters) - Oncolytics Biotech Inc ONC.TO : * ONCOLYTICS BIOTECH® REPORTS 2021 FIRST QUARTER DEVELOPMENT HIGHLIGHTS AND FINANCIAL RESULTS * Q1 LOSS PER SHARE C$0.13 * AS OF...
April 12 (Reuters) - Oncolytics Biotech Inc ONC.TO : * ONCOLYTICS BIOTECH® PRESENTS PRECLINICAL DATA ON PELAREOREP-BASED COMBINATION THERAPIES AT AACR ANNUAL MEETING * ONCOLYTICS...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Oncolytics Biotech Inc. is a biotechnology company, which is engaged in developing pelareorep, an intravenously delivered immunotherapeutic agent. The Company is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
|Average||7.37 (+323.35% Upside)|
|No. of Analysts||3|